Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04WHM
|
|||
| Former ID |
DIB004985
|
|||
| Drug Name |
G0-203-2c
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 1/2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2] | ||
| Company |
Genus 0ncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | Modulator | [3] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genus 0ncology. | |||
| REF 3 | Clinical pipeline report, company report or official report of Genus Oncology. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.